Health Canada has suspended the operating licence of a Grifols facility located in Winnipeg, theglobeandmail.com reports. The suspension was announced on Wednesday, September 23, 2026, according to the same outlet.
The Globe and Mail's report identifies the site as belonging to Grifols but does not set out the reasons behind Health Canada's decision, nor does it indicate how long the suspension is expected to last. The reporting also does not say what operations take place at the Winnipeg location or how many people work there.
Grifols is a company in the blood plasma business, and Health Canada is the federal regulator responsible for licensing sites of this kind. A suspended licence means the site cannot continue licensed activity while the suspension is in effect, though the source material does not specify what that means for this particular facility.
Details beyond the suspension itself — including the regulator's stated grounds, any response from Grifols, and the effect on supply — have not been reported in the material available.
What to watch next: whether Health Canada publishes its reasons for the suspension and whether Grifols issues a statement or a timeline for restoring the licence.
